In our study, patients who received DEC-VEN primarily had de novo AML, intermediate-risk cytogenetics, and wild-type TP53 (Table 1), which likely does not explain the inferior survival of patients in this group. This evidence concerns the gene TP53 and acute myeloid leukemia.